Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Authors

• William Kelly

Publication/Presentation Date

5-2019

Volume

37

Issue

15

Published In/Presented At

DOI: 10.1200/JCO.2019.37.15_suppl.5045

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article